Vaccine
development
service

Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine Bilthoven, the Netherlands, 12 September 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable…

• Additional pre-clinical data of Avacc 10® indicate reduction in upper respiratory tract viral load and cross neutralization of variants of concern
• Avacc 10® toxicology data support the start of a phase I clinical trial in Q4 2022

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant Bilthoven, the Netherlands / Munich, Germany, 6 July 2022 – Intravacc, a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines and the…

• Total amount of €2.5 million for amyotrophic lateral sclerosis (ALS) vaccine development
• ALS vaccine is targeting the most common genetic ALS variant
• 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors Bilthoven, the Netherlands, 5 July 2022 – Intravacc B.V., a world leader in translational research and development of preventive and therapeutic vaccines, today announced…

• Publication annual report 2021
• Appointment of a Chief Business Officer
• Appointment of a Director vaccine process development
• Chief Financial Officer joins the Board of Directors